Table 3 Relationship of MYCN status to the clinicobiological characteristics of BM metastatic NB (n = 81)
Characteristics | Total n (%) | MYCN-amplification n (%) | MYCN-normal n (%) | P values* |
|---|---|---|---|---|
Gender | ||||
Male | 51 (63.0) | 7 (53.8) | 44 (64.7) | 0.536 |
Female | 30 (37.0) | 6 (46.2) | 24 (35.3) | |
Age (months) | ||||
<12 | 3 (3.7) | 0 (0) | 3 (4.4) | 0.038 |
12–18 | 4 (4.9) | 2 (15.4) | 2 (2.9) | |
18–24 | 11 (13.6) | 4 (30.8) | 7 (10.3) | |
>24 | 63 (77.8) | 7 (53.8) | 56 (82.4) | |
Treatment group | ||||
LR | 3 (3.7) | 0 (0) | 3 (4.4) | 0.999 |
IR | 3 (3.7) | 0 (0) | 3 (4.4) | |
HR | 75 (92.6) | 13 (100) | 62 (91.2) | |
LDH (IU/L) | ||||
<1500 | 55 (67.9) | 3 (23.1) | 52 (76.5) | <0.001 |
≥1500 | 26 (31.1) | 10 (76.9) | 16 (23.5) | |
NSE (UG/L) | ||||
<100 | 10 (12.3) | 0 (0) | 10 (14.7) | 0.352 |
≥100 | 71 (87.7) | 13 (100) | 58 (85.3) | |
Primary site | ||||
Abdomen | 73 (90.1) | 12 (92.3) | 61 (89.7) | 0.999 |
Thorax | 6 (7.4) | 1 (7.7) | 5 (7.4) | |
Others | 2 (2.5) | 0 (0) | 2 (2.9) | |
Event | ||||
No event | 54 (66.7) | 5 (38.5) | 49 (72.1) | 0.026 |
Event | 27 (33.3) | 8 (61.5) | 19 (27.9) | |